Evidence map›Paper›PMID 42050673›Full record

ReviewOrphanet journal of rare diseases2026

Fostering continuous quality improvement in a European rare disease network: Where are we now?

Linde Margriet van der Kamp, Sara Román Galdrán, Willemijn F E Irvine, Daniel Rossi, Romee van Steekelenburg, ERNICA Representatives, René M H Wijnen, Erwin Ista, Olivia K C Spivack

Abstract readReview
In one paragraph

Review in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Linde Margriet van der Kamp *European Reference Network for Rare Inherited and Congenital Anomalies (ERNICA), Rotterdam, The Netherlands. L.vanderkamp@erasmusmc.nl.ORCID http://orcid.org/0009-0004-3606-3019
Sara Román Galdrán *European Reference Network for Rare Inherited and Congenital Anomalies (ERNICA), Rotterdam, The Netherlands.
Willemijn F E IrvineEuropean Reference Network for Rare Inherited and Congenital Anomalies (ERNICA), Rotterdam, The Netherlands.
Daniel RossiEuropean Reference Network for Rare Inherited and Congenital Anomalies (ERNICA), Rotterdam, The Netherlands.
Romee van SteekelenburgEuropean Reference Network for Rare Inherited and Congenital Anomalies (ERNICA), Rotterdam, The Netherlands.
ERNICA Representatives
René M H WijnenEuropean Reference Network for Rare Inherited and Congenital Anomalies (ERNICA), Rotterdam, The Netherlands.
Erwin IstaDepartment of Neonatal and Pediatric Intensive Care, Division of Pediatric Intensive Care, Erasmus MC Sophia Children's Hospital, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
Olivia K C SpivackEuropean Reference Network for Rare Inherited and Congenital Anomalies (ERNICA), Rotterdam, The Netherlands.

Funding

EU4Health Programme 2023-2027 (Project 101155831 - EU4H2023-ERN-IBA). EU4Health Programme 2023-2027 (Project 101155831 - EU4H2023-ERN-IBA).
6 · The paper itself

Abstract

backgroundThe European Reference Network for rare Inherited and Congenital Anomalies (ERNICA) aims to improve care for patients with rare and complex digestive and gastrointestinal diseases across Europe through cross-border collaboration. In a previous publication, we introduced the ERNICA quality cycle as a structured framework for the continuous improvement of care. This framework focuses on five steps: Describing the desired quality of care, promoting implementation, measuring care quality, evaluating clinical practice and performing research. MAIN BODY: Focusing on three selected ERNICA conditions (omphalocele, rectosigmoid Hirschsprung’s disease and esophageal atresia), this paper reports on progress made across all steps of the ERNICA quality cycle. Activities include the development of clinical guidelines and core quality indicator sets and efforts to standardise clinical definitions. To support successful guideline implementation, both a central implementation support team and a network of local implementation leads have been established. Quality measurement is facilitated through the European Pediatric Surgical Audit (EPSA), which enables real-world data collection, benchmarking and the evaluation of clinical practice. Steps have been taken to identify and fill knowledge gaps through high-quality research. Efforts include the development of core outcome sets, exploring the use of EPSA data for research purposes, and sharing lessons learnt from ERNICA-endorsed randomised controlled trials.

conclusionThe progress presented in this paper reflects ERNICA’s growing impact and sustained dedication to improving care and outcomes for patients with rare digestive and gastrointestinal diseases across Europe. This update aims to keep stakeholders informed, promote transparency, and facilitate continuous learning and collaboration. Building on lessons learnt, future efforts will involve optimising ongoing initiatives and scaling the ERNICA quality cycle to include additional diseases. Although these efforts are not without challenge, ERNICA remains committed to improving care quality across its connected centres and beyond.

Indexed as

Quality ImprovementRare DiseasesEuropeHumansClinical practice guidelinesCross-border collaborationERNICAEuropean reference networkImplementation scienceQuality improvementRare diseases

Identifiers

PMID42050673
PMCPMC13127023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.